, Volume 67, Issue 9, pp 1359–1378 | Cite as


A Review of its Use in Essential Hypertension, Type 1 Diabetic Nephropathy and Chronic Heart Failure
  • Dean M. Robinson
  • Monique P. Curran
  • Katherine A. Lyseng-Williamson
Adis Drug Evaluation



Imidapril (Tanatril™), through its active metabolite imidaprilat, acts as an ACE inhibitor to suppress the conversion of angiotensin I to angiotensin II and thereby reduce total peripheral resistance and systemic blood pressure (BP).

In clinical trials, oral imidapril was an effective antihypertensive agent in the treatment of mild to moderate essential hypertension. Some evidence suggests that imidapril also improves exercise capacity in patients with chronic heart failure (CHF) and reduces urinary albumin excretion rate in patients with type 1 diabetes mellitus. Imidapril was well tolerated, with a lower incidence of dry cough than enalapril or benazepril, and is a first choice ACE inhibitor for the treatment of mild to moderate essential hypertension.

Pharmacological Properties

The active metabolite of imidapril is imidaprilat, which inhibits the conversion of angiotensin I to angiotensin II. Lowering of plasma and tissue angiotensin II levels results in peripheral vasodilation, reduced systemic BP, renoprotective effects in patients with type 1 diabetes, and decreased renal sodium and water retention.

After multidose oral administration in patients with hypertension, steady-state maximum plasma concentrations of imidapril (≈30 ng/mL) and imidaprilat (≈20 ng/mL) are achieved in a median time of 2 and 5 hours. In healthy men 25.5% of a single dose of imidapril 10mg was excreted in the urine within 24 hours. Elimination occurs primarily through excretion in the urine (≈40%) and faeces (≈50%); after oral administration in healthy volunteers, the terminal elimination half-life of imidaprilat is ≈24 hours.

Therapeutic Efficacy

In randomised controlled trials, oral imidapril was effective in the treatment of adults with mild to moderate essential hypertension. In short-term (2- and 4-week) dose-finding trials, imidapril dosages of 10–40 mg/day were significantly more effective than placebo, inducing 11–15mm Hg reductions in sitting diastolic BP (sDBP; primary endpoint). In comparative 12- and 24-week trials, imidapril 5–20 mg/day induced reductions in mean sDBP of 10–15mm Hg that did not differ significantly from those induced by hydrochlorothiazide 12.5–50 mg/day or captopril 50–100 mg/day (primary endpoint), nor those induced by enalapril 5–10 mg/day or nifedipine sustained release (SR) 40–80 mg/day (secondary endpoint). In addition, reductions in sDBP and sitting systolic BP (co-primary endpoints) with imidapril did not differ from those induced by candesartan 4–16 mg/day. Favourable reductions in sDBP were maintained during 6-month and 52-week noncomparative trials.

In patients with type 1 diabetes, the urinary albumin excretion rate (a marker of nephropathy) increased by 72% in placebo recipients, but declined by 41% in imidapril 5 mg/day and by 6% in captopril 37.5 mg/day recipients during a mean treatment period of 1.5 years.

In patients with CHF, mean total exercise time increased from baseline in imidapril 2.5–10 mg/day recipients in a dose-related manner after 12-weeks of treatment; a 9.7% increase with imidapril 10 mg/day was significantly greater than the change with placebo (+0.7%).


Overall, imidapril was relatively well tolerated, with an incidence of adverse events in pooled analyses of data from clinical trials and post-marketing surveillance (n = 6632) of 6.6%. The most commonly reported adverse events were cough, hypotension, dizziness and pharyngeal discomfort. During 2- and 4-week trials, the overall incidence of adverse events was 26% and 40% in recipients of imidapril 2.5–40 mg/day compared with 35% and 37% in placebo recipients. In comparative trials, the incidence of treatment-related adverse events in imidapril versus enalapril recipients in two 12-week trials were 5.6% versus 12.2% and 12.0% versus 14.1%; in other 12-week trials treatment-related adverse events were observed in 24.2% of imidapril versus 41.7% of nifedipine SR, and 20.7% of imidapril versus 46.4% of captopril recipients, while the overall incidence of adverse events in imidapril versus candesartan recipients was 11.7% versus 16.1%. The incidences of adverse events in a 24-week trial were 46.0% with imidapril and 52.8% with hydrochlorothiazide. In longer-term trials, adverse events were reported by 61.6% of imidapril recipients in the 52-week trial; however, only 1.7% of imidapril recipients in a 6-month field trial experienced adverse events considered related to ACE inhibitor treatment.

In prospective investigations in hypertensive patients, switching to imidapril did not reduce the incidence of cough (a class effect of ACE inhibitors) in a small open-label trial in hypertensive patients already experiencing ACE-inhibitor induced cough; however, in a large crossover trial, the incidence of cough with imidapril (15.2%) was less than half that with enalapril (38.6%). In addition, cough disappeared in 52.9% of enalapril recipients switched to imidapril, and in patients without cough during imidapril treatment, switching to enalapril induced cough in 20.9%. In contrast, in patients without cough during initial enalapril treatment, only 0.9% developed cough during subsequent imidapril treatment. In a second large, double-blind crossover trial, the incidence of cough was significantly lower in imidapril than benazepril recipients.


  1. 1.
    Song JC, White CM. Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet 2002; 41 (3): 207–24PubMedCrossRefGoogle Scholar
  2. 2.
    World Health Organization. The World Health Report 2002: reducing risks, promoting healthy life [online]. Available from URL: http://www.who.int/whr/2002/en/index.html [Accessed 2006 Jul 28]
  3. 3.
    Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990 Apr 7; 335 (8693): 827–38PubMedCrossRefGoogle Scholar
  4. 4.
    Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: full text (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology [online]. Available from URL: http://escol.es-cardio.org/ [Accessed 2006 Aug 9]
  5. 5.
    Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to update the 2001 guidelines for the evaluation and management of heart failure). Developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005 Sep 20; 112 (12): el54–235CrossRefGoogle Scholar
  6. 6.
    Molitch ME, DeFronzo RA, Franz MJ, et al. Nephropathy in diabetes. Diabetes Care 2004 Jan; 27 Suppl. 1: S79–83PubMedCrossRefGoogle Scholar
  7. 7.
    TANATRIL® tablets 2.5 and 5mg (imidapril hydrochloride); Japanese prescribing information (English version). Osaka: Tanabe Sciyaku Co. Ltd, 2005 JunGoogle Scholar
  8. 8.
    Dews I, VandenBurg M. A 24-week dose-titration study of the angiotensin-converting enzyme inhibitor imidapril in the treatment of mild-to-moderate essential hypertension in the elderly. J Int Med Res 2001 Mar–Apr, 100-7Google Scholar
  9. 9.
    Data on File. Tanabe Sciyaku Co. Ltd, 2007Google Scholar
  10. 10.
    Summary of product characteristics: Tanatril 5 mg tablet. Tanabe Europe N.V., 2002 Nov 11Google Scholar
  11. 11.
    Oshima S, Ogawa H, Mizuno Y, et al. The effects of the angiotensin-converting enzyme inhibitor imidapril on plasma plasminogen activator inhibitor activity in patients with acute myocardial infarction. Am Heart J 1997 Nov; 134 (Pt 1): 961–6PubMedCrossRefGoogle Scholar
  12. 12.
    Harder S, Thürmann PA. Pharmacokinetic and pharmacodynamic interaction trial after repeated oral doses of imidapril and digoxin in healthy volunteers. Br J Clin Pharmacol 1997 May; 43: 475–80PubMedCrossRefGoogle Scholar
  13. 13.
    Kubo M, Kato J, Ochiai T, et al. Pharmacological studies on (4S)-1 -methyl-3- (2s)-2-[n-( (1s)-l -ethoxycarbonyl-3-phenyl-propyl)amino]propionyl-2-oxo-imidazolidine-4-carboxylic acid hydrochloride (TA-6366), a new ACE inhibitor: I. ACE inhibitory and antihypertensive activities. Jpn J Pharmacol 1990; 53: 201–10PubMedCrossRefGoogle Scholar
  14. 14.
    Kubo M, Ochiai T, Kato J, et al. Pharmacological studies on TA-6366, a new ACE inhibitor: II. Effect of long-term administration from the pre-hypertensive stage on blood pressure, relative heart weight and ACE activity of various tissues in spontaneously hypertensive rats (SHRs). Jpn J Pharmacol 1991; 57: 517–26PubMedCrossRefGoogle Scholar
  15. 15.
    VandenBurg MJ, Mackay EM, Dews I, et al. Dose finding studies with imidapril: a new ACE inhibitor. Br J Clin Pharmacol 1994 Mar; 37: 265–72PubMedCrossRefGoogle Scholar
  16. 16.
    van Veldhuisen DJ, Genth-Zotz S, Brouwer J, et al. High-versus low-dose ACE inhibition in chronic heart failure: a double-blind, placebo-controlled study of imidapril. J Am Coll Cardiol 1998 Dec; 32: 1811–8PubMedCrossRefGoogle Scholar
  17. 17.
    Sato A, Saruta T. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res 2001 Jan–Feb; 29 (1): 13–21PubMedGoogle Scholar
  18. 18.
    Shah NC, Pringle S, Struthers A. Aldosterone blockade over and above ACE-inhibitors in patients with coronary artery disease but without heart failure. J Renin Angiotensin Aldosterone Syst 2006; 7 (1): 20–30PubMedCrossRefGoogle Scholar
  19. 19.
    Kohno I, Ijiri H, Takusagawa M, et al. Effect of imidapril in dipper and nondipper hypertensive patients: comparison between morning and evening administration. Chronobiol Int 2000; 17 (2): 209–19PubMedCrossRefGoogle Scholar
  20. 20.
    Huang PJ, Chien KL, Chen MF, et al. Efficacy and safety of imidapril in patients with essential hypertension: a double-blind comparison with captopril. Cardiology 2001; 95 (3): 146–50PubMedCrossRefGoogle Scholar
  21. 21.
    Saruta T, Omae T, Kuramochi M, et al. Imidapril hydrochloride in essential hypertension: a double-blind comparative study using enalapril maleate as a control. J Hypertens 1995 Sep; 13 Suppl. 3: S23–30CrossRefGoogle Scholar
  22. 22.
    van der Does R, Euler R. Comparison of the antihypertensive effect of imidapril and enalapril in the treatment of mild to moderate essential hypertension: a randomized, double-blind, parallel-group study. Curr Ther Res Clin Exp 2001 Jun; 62: 437–50CrossRefGoogle Scholar
  23. 23.
    van der Does R, Euler R. A randomized, double-blind, parallel-group study to compare the anti-hypertensive effects of imidapril and nifedipine in the treatment of mild-to-moderate essential hypertension. J Int Med Res 2001 May–Jun; 29: 154–162PubMedGoogle Scholar
  24. 24.
    Dews I, VandenBurg M. A 52-week, open-label, dose-titration safety study of imidapril in the treatment of mild to moderate hypertension. Curr Ther Res Clin Exp 2001 Feb; 62: 167–76CrossRefGoogle Scholar
  25. 25.
    Demolis P, Annane D, Duhaze P, et al. Systemic, regional and cerebral hemodynamic effects of a new angiotensin converting enzyme inhibitor, imidapril, in healthy volunteers. Fundam Clin Pharmacol 1994; 8 (1): 80–9PubMedCrossRefGoogle Scholar
  26. 26.
    Pinto YM, van Veldhuisen DJ, Tjon-Ka-Jie RT, et al. Dose-finding study of imidapril, a novel angiotensin converting enzyme inhibitor, in patients with stable chronic heart failure. Eur J Clin Pharmacol 1996 Jun; 50: 265–8PubMedCrossRefGoogle Scholar
  27. 27.
    Hirata Y, Hayakawa H, Kakoki M, et al. Nitric oxide release from kidneys of hypertensive rats treated with imidapril. Hypertension 1996; 27: 672–8PubMedCrossRefGoogle Scholar
  28. 28.
    Suda O, Tsutsui M, Morishita T, et al. Long-term treatment with imidapril but not with nifedipine enhances plasma NOx concentration in patients with essential hypertension. J Pharmacol Sci 2006 Jun; 101 (2): 159–65PubMedCrossRefGoogle Scholar
  29. 29.
    Higashi Y, Oshima T, Sasaki S, et al. Angiotensin-converting enzyme inhibition, but not calcium antagonism, improves a response of the renal vasculture to L-arginine in patients with essential hypertension. Hypertension 1998 Jul; 32: 16–24PubMedCrossRefGoogle Scholar
  30. 30.
    Higashi Y, Sasaki S, Nakagawa K, et al. Effect of the angiotensin-converting enzyme inhibitor imidapril on reactive hyperemia in patients with essential hypertension: relationship between treatment periods and resistance artery endothelial function. J Am Coll Cardiol 2001 Mar 1; 37 (3): 863–70PubMedCrossRefGoogle Scholar
  31. 31.
    Higashi Y, Sasaki S, Nakagawa K, et al. Severity of hypertension affects improved resistance artery endothelial function by angiotensin-converting enzyme inhibition. J Cardiovasc Pharmacol 2002 May; 39 (5): 668–76PubMedCrossRefGoogle Scholar
  32. 32.
    Higashi Y, Sasaki S, Nakagawa K, et al. A comparison of angiotensin-converting enzyme inhibitors, calcium antagonists, beta-blockers and diuretic agents on reactive hyperemia in patients with essential hypertension: a multicenter study. J Am Coll Cardiol 2000 Feb; 35 (2): 284–91PubMedCrossRefGoogle Scholar
  33. 33.
    Chen R, Iwai M, Wu L, et al. Important role of nitric oxide in the effect of angiotensin-converting enzyme inhibitor imidapril on vascular injury. Hypertension 2003 Oct; 42 (4): 542–7PubMedCrossRefGoogle Scholar
  34. 34.
    Hosoya K, Takeda K, Nishikimi T, et al. Force-length relationship in dogs as a measure of protective effect of imidapril on regional myocardial ischemia and reperfusion injury. Eur J Pharmacol 2000; 390 (1–2): 157–66PubMedCrossRefGoogle Scholar
  35. 35.
    Fujiwara T, Yuasa H, Ogiku N, et al. Histopathological investigation on salt-loaded stroke-prone spontaneously hypertensive rats, whose biochemical parameters of renal dysfunction were ameliorated by administration of imidapril. Jpn J Pharmacol 1994; 66: 231–40PubMedCrossRefGoogle Scholar
  36. 36.
    Hamaguchi A, Kim S, Wanibuchi H, et al. Imidapril inhibits increased transforming growth factor-β1 expression in remnant kidney model. Eur J Pharmacol 1997 Jul 16; 331: 27–30PubMedCrossRefGoogle Scholar
  37. 37.
    Satonaka H, Suzuki E, Hayakawa H, et al. Long-term effect of imidapril hydrochloride compared with dilazep hydrochloride administration on blood pressure and renal function in patients with chronic glomerulonephritis. Int Heart J 2005 Jul; 46 (4): 701–10PubMedCrossRefGoogle Scholar
  38. 38.
    Yoshitomi Y, Kojima S, Yano M, et al. Long-term effects of bisoprolol compared with imidapril on left ventricular remodeling after reperfusion in acute myocardial infarction: an angiographic study in patients with maintained vessel patency. Am Heart J 2000 Dec; 140 (6): E27 (1–7)CrossRefGoogle Scholar
  39. 39.
    Soejima H, Ogawa H, Yasue H, et al. Effects of imidapril therapy on endogenous fibrinolysis in patients with recent myocardial infarction. Clin Cardiol 1997 May; 20: 441–5PubMedCrossRefGoogle Scholar
  40. 40.
    Tokudome M, Uno T, Sato Y. Effects of imidapril treatment on insulin resistance in diabetic patients [in Japanese]. J Jpn Diabetes Soc 2003; 46 (8): 685–8Google Scholar
  41. 41.
    Arai T, Yoshimi N, Fujiwara H, et al. Serum substance P concentrations and silent aspiration in elderly patients with stroke [letter]. Neurology 2003 Dec 9; 61 (11): 1625–6PubMedCrossRefGoogle Scholar
  42. 42.
    Arai T, Yasuda Y, Takaya T, et al. Angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, and symptomless dysphagia [letter]. Chest 2000 Jun; 117 (6): 1819–20PubMedCrossRefGoogle Scholar
  43. 43.
    Sakamoto KI, Sugimoto KI, Fujimura A. Different inhibition of enalaprilat and imidaprilat on bradykinin metabolizing enzymes. Life Sci 2000; 67 (18): 2159–65PubMedCrossRefGoogle Scholar
  44. 44.
    Hosoya K, Ishimitsu T. Protection of the cardiovascular system by imidapril, a versatile angiotensin-converting enzyme inhibitor. Cardiovasc Drug Rev 2002 Summer; 20 (2): 93–110PubMedCrossRefGoogle Scholar
  45. 45.
    Harder S, Thürmann PA, Ungethüm W. Single dose and steady state pharmacokinetics and pharmacodynamics of the ACE-inhibitor imidapril in hypertensive patients. Br J Clin Pharmacol 1998 Apr; 45: 377–80PubMedCrossRefGoogle Scholar
  46. 46.
    MacGregor GA. Expert report on the clinical documentation. Tanabe Sciyaku Co. Ltd, 1996. (Data on file)Google Scholar
  47. 47.
    Sabharwal NK, Swinburn J, Lahiri A, et al. Effect of imidapril and nifedipine on left ventricular hypertrophy in untreated hypertension. Clin Drug Invest 2005; 25 (6): 367–75CrossRefGoogle Scholar
  48. 48.
    Takahashi M, Minatoguchi S, Nishigaki K, et al. Long-term and strict blood pressure lowering by imidapril reverses left ventricular hypertrophy in patients with essential hypertension: an evaluation using a novel indicator of burden on the left ventricle. Hypertens Res 2006 Feb; 29 (2): 89–94PubMedCrossRefGoogle Scholar
  49. 49.
    Sasaguri M, Noda K, Tashiro E, et al. The regression of left ventricular hypertrophy by imidapril and the reduction of serum procollagen type III amino-terminal peptide in hypertensive patients. Hypertens Res 2000 Jul; 23: 317–22PubMedCrossRefGoogle Scholar
  50. 50.
    Katayama S, Kikkawa R, Isogai S, et al. Effect of captopril or imidapril on the progression of diabetic nephropathy in Japanese with type 1 diabetes mellitus: a randomized controlled study (JAPAN-IDDM) [published erratum appears in Diabetes Res Clin Pract 2002 Jul; 57 (1): 71]. Diabetes Res Clin Pract 2002 Feb; 55: 113–21PubMedCrossRefGoogle Scholar
  51. 51.
    Hoogkamer JFW, Kleinbloesem CH, Nokhodian A, et al. Pharmacokinetics of imidapril and its active metabolite imidaprilat following single dose and during steady state in patients with chronic renal failure. Eur J Clin Pharmacol 1998 Mar; 54: 59–61PubMedCrossRefGoogle Scholar
  52. 52.
    Hoogkamer JFW, Kleinbloesem CH, Nokhodian A, et al. Pharmacokinetics of imidapril and its active metabolite imidaprilat following single dose and during steady state in patients with impaired liver function. Eur J Clin Pharmacol 1997 Feb; 51: 489–91PubMedCrossRefGoogle Scholar
  53. 53.
    Hirota Y, Kawamura K, Ooyagi A. Phase I study of TA-6366 (I): single oral administration [in Japanese]. J Clin Ther Med 1992; 8: 507–22Google Scholar
  54. 54.
    Breithaupt-Grögler K, Ungethüm W, Meurer-Witt B, et al. Pharmacokinetic and dynamic interactions of the angiotensin-converting enzyme inhibitor imidapril with hydrochlorothia-zide, bisoprolol and nilvadipine. Eur J Clin Pharmacol 2001 Jul; 57: 275–84PubMedCrossRefGoogle Scholar
  55. 55.
    Palma Gámiz JL, Pêgo M, Contreras EM, et al. A twelve-week, multicenter, randomized, double-blind, parallel-group, noninferiority trial of the antihypertensive efficacy and tolera-bility of imidapril and candesartan in adult patients with mild to moderate essential hypertension: The Iberian Multicenter Imidapril study on hypertension (IMISH). Clin Ther 2006 Dec; 28 (12): 2040–51PubMedCrossRefGoogle Scholar
  56. 56.
    Zweiker R, Stoschitzky K, Maier R, et al. Efficacy and safety of the ACE-inhibitor imidapril in patients with essential hypertension. Acta Med Austriaca 2002; 29 (2): 72–6PubMedCrossRefGoogle Scholar
  57. 57.
    Shionoiri H, Takasaki I, Minamisawa K, et al. Cough-challenge trial with a new angiotensin-converting enzyme inhibitor, imidapril. J Clin Pharmacol 1998 May; 38: 442–6PubMedGoogle Scholar
  58. 58.
    Liu G. Comparative study of hypotensive efficacy and the cough occurrence of imidapril versus benazepril [in Chinese]. Chin J Cardiol 2004 Apr; 32 (4): 304–7Google Scholar
  59. 59.
    Saruta T, Arakawa K, Iimura O, et al. Difference in the incidence of cough induced by angiotensin converting enzyme inhibitors: a comparative study using imidapril hydrochloride and enalapril maleate. Hypertens Res Clin Exp 1999 Sep; 22: 197–202CrossRefGoogle Scholar
  60. 60.
    Dykewicz MS. Cough and angioedema from angiotensin-converting enzyme inhibitors: new insights into mechanisms and management. Curr Opin Allergy Clin Immunol 2004 Aug; 4 (4): 267–70PubMedCrossRefGoogle Scholar
  61. 61.
    Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. National High Blood Pressure Education Program Coordinating Committee. JAMA 2003 May 21; 289 (19): 2560–72PubMedCrossRefGoogle Scholar
  62. 62.
    Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003 Nov 8; 362 (9395): 1527–35PubMedCrossRefGoogle Scholar
  63. 63.
    Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998 Jun 13; 351 (9118): 1755–62PubMedCrossRefGoogle Scholar
  64. 64.
    Wang TJ, Vasan RS. Epidemiology of uncontrolled hypertension in the United States. Circulation 2005 Sep 13; 112 (11): 1651–62PubMedCrossRefGoogle Scholar
  65. 65.
    Andersson OK, Almgren T, Persson B, et al. Survival in treated hypertension: follow up study after two decades. BMJ 1998 Jul 18; 317 (7152): 167–71PubMedCrossRefGoogle Scholar
  66. 66.
    Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002 Dec 14; 360 (9349): 1903–13PubMedCrossRefGoogle Scholar
  67. 67.
    Laurent S. Guidelines from the British Hypertension Society: the lower the pressure the better. BMJ 2004 Mar 13; 328 (7440): 593–4PubMedCrossRefGoogle Scholar
  68. 68.
    2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. European Society of Hypertension-European Society of Cardiology Guidelines Committee [published erratum appears in J Hypertens 2003 Nov; 21 (11): 2203–4 and J Hypertens 2004 Feb; 22 (2): 435]. J Hypertens 2003 Jun; 21 (6): 1011–53CrossRefGoogle Scholar
  69. 69.
    Williams B, Poulter NR, Brown MJ, et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004 Mar; 18 (3): 139–85PubMedCrossRefGoogle Scholar
  70. 70.
    Whitworth JA. 2003 World Health Organization (WHO)/Inter-national Society of Hypertension (ISH) statement on management of hypertension. World Health Organization, International Society of Hypertension Writing Group. J Hypertens 2003 Nov; 21 (11): 1983–92PubMedCrossRefGoogle Scholar
  71. 71.
    Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists’ Collaboration. Lancet 2000 Dec 9; 356 (9246): 1955–64PubMedCrossRefGoogle Scholar
  72. 72.
    Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003 May 21; 289 (19): 2534–44PubMedCrossRefGoogle Scholar
  73. 73.
    Turnbull F, Neal B, Algert C, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005 Jun 27; 165 (12): 1410–9PubMedCrossRefGoogle Scholar
  74. 74.
    Sever PS, Poulter NR, Elliott WJ, et al. Blood pressure reduction is not the only determinant of outcome. Circulation 2006 Jun 13; 113 (23): 2754–72PubMedCrossRefGoogle Scholar
  75. 75.
    Verma S, Strauss M. Angiotensin receptor blockers and myocar-dial infarction. BMJ 2004 Nov 27; 329 (7477): 1248–9PubMedCrossRefGoogle Scholar
  76. 76.
    McDonald MA, Simpson SH, Ezekowitz JA, et al. Angiotensin receptor blockers and risk of myocardial infarction: systematic review. BMJ 2005 Oct 15; 331 (7521): 873–6PubMedCrossRefGoogle Scholar
  77. 77.
    Verdecchia P, Angeli F, Gattobigio R, et al. Do angiotensin II receptor blockers increase the risk of myocardial infarction? Eur Heart J 2005 Nov; 26 (22): 2381–6PubMedCrossRefGoogle Scholar
  78. 78.
    Volpe M, Mancia G, Trimarco B. Angiotensin II receptor blockers and myocardial infarction: deeds and misdeeds. J Hypertens 2005 Dec; 23 (12): 2113–8PubMedCrossRefGoogle Scholar
  79. 79.
    Volpe M, Tocci G, Savoia C. Angiotensin II receptor blockers and coronary artery disease: ‘presumed innocents’ [letter]. Eur Heart J 2006 Jun; 27 (12): 1506–7PubMedCrossRefGoogle Scholar
  80. 80.
    Strauss MH, Hall AS, Tsuyuki RT, et al. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation 2006 Aug 22; 114 (8): 838–54PubMedCrossRefGoogle Scholar
  81. 81.
    Strauss MH, Hall AS. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation 2006 Aug 22; 114 (8): 838–54PubMedCrossRefGoogle Scholar
  82. 82.
    Tsuyuki RT, McDonald MA. Angiotensin receptor blockers do not increase risk of myocardial infarction. Circulation 2006 Aug 22; 114 (8): 855–60PubMedCrossRefGoogle Scholar
  83. 83.
    National Collaborating Centre for Chronic Conditions. Hypertension: management of hypertension in adults in primary care. Partial update. London: Royal College of Physicians, 2006 [online]. Available from URL: http://www.nice.org.uk/download.aspx?o=CG034fullguideline [Accessed 2006 Aug10]Google Scholar
  84. 84.
    Harvey JN. Diabetic nephropathy. BMJ 2002 Jul 13; 325 (7355): 59–60PubMedCrossRefGoogle Scholar
  85. 85.
    National Institute for Clinical Excellence. Chronic heart failure: management of chronic heart failure in adults in primary and secondary care [online]. Available from URL: http://www.nice.org.uk [Accessed 2006 Aug 15]
  86. 86.
    Dolezal T. Imidapril in heart failure. J Renin Angiotensin Al-dosterone Syst 2006 Sep 29; 7 (3): 146–54CrossRefGoogle Scholar
  87. 87.
    Arai T, Yasuda Y, Tayaka. T, et al. ACE inhibitors and symp-tomless dysphagia [letter]. Lancet 1998; 352 (9122): 115–6PubMedCrossRefGoogle Scholar
  88. 88.
    Marik PE, Kaplan D. Aspiration pneumonia and dysphagia in the elderly. Chest 2003 Jul; 124 (1): 328–36PubMedCrossRefGoogle Scholar
  89. 89.
    Arai T, Yasuda Y, Toshima S, et al. ACE inhibitors and pneumonia in elderly people [letter]. Lancet 1998 Dec 12; 352 (9144): 1937–8PubMedCrossRefGoogle Scholar
  90. 90.
    Ohkubo T, Chapman N, Neal B, et al. Effects of an angiotensin-converting enzyme inhibitor-based regimen on pneumonia risk. Am J Respir Crit Care Med 2004 May 1; 169 (9): 1041–5PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2007

Authors and Affiliations

  • Dean M. Robinson
    • 1
    • 2
  • Monique P. Curran
    • 1
    • 2
  • Katherine A. Lyseng-Williamson
    • 1
    • 2
  1. 1.Wolters Kluwer Health / AdisMairangi Bay, North Shore, AucklandNew Zealand
  2. 2.Wolters Kluwer HealthConshohockenUSA

Personalised recommendations